CTLA4 and melanoma: A phase I clinical trial of dual blockade of CTLA-4 (ipilimumab) plus VEGF (bevacizumab) showed increased tumor antigen recognition, tumor-associated endothelial activation, and infiltration of T cells in melanomas (168).